Challenges and opportunities in developing Actinium-225 radiopharmaceuticals.
Journal
Nuclear medicine communications
ISSN: 1473-5628
Titre abrégé: Nucl Med Commun
Pays: England
ID NLM: 8201017
Informations de publication
Date de publication:
01 Sep 2022
01 Sep 2022
Historique:
entrez:
11
8
2022
pubmed:
12
8
2022
medline:
13
8
2022
Statut:
ppublish
Résumé
Actinium-225 (225Ac) has emerged as a promising therapeutic radioisotope for targeted alpha therapy. It emits net four alpha particles during its decay to stable daughter bismuth-209, rightly called an in-vivo nano-generator. Compared to the worldwide demand of 225Ac, the amount produced via depleted thorium-229 sources is minimal, making it an expensive radionuclide. However, many research groups are working on optimizing the parameters for the production of 225Ac via different routes, including cyclotrons, reactors and high-energy linear accelerators. The present review article focuses on the various aspects associated with the development of 225Ac radiopharmaceuticals. It includes the challenges and opportunities associated with the production methods, labeling chemistry, in-vivo kinetics and dosimetry of 225Ac radiopharmaceuticals. A brief description is also given about the 225Ac radiopharmaceuticals at preclinical stages, clinical trials and used routinely.
Identifiants
pubmed: 35950353
doi: 10.1097/MNM.0000000000001594
pii: 00006231-202209000-00002
doi:
Substances chimiques
Actinium-225
0
Radioisotopes
0
Radiopharmaceuticals
0
Actinium
NIK1K0956U
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
970-977Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Références
Dash A, Knapp FF, Pillai MR. Targeted radionuclide therapy–an overview. Curr Radiopharm 2013; 6:152–180.
Gudkov SV, Shilyagina NY, Vodeneev VA, Zvyagin AV. Targeted radionuclide therapy of human tumors. Int J Mol Sci 2015; 17:E33.
Allen BJ, Raja C, Rizvi S, Li Y, Tsui W, Zhang D, et al. Targeted alpha therapy for cancer. Phys Med Biol 2004; 49:3703–3712.
Baidoo KE, Yong K, Brechbiel MW. Molecular pathways: targeted α-particle radiation therapy. Clin Cancer Res 2013; 19:530–537.
Marcu L, Bezak E, Allen BJ. Global comparison of targeted alpha vs targeted beta therapy for cancer: in vitro, in vivo and clinical trials. Crit Rev Oncol Hematol 2018; 123:7–20.
McDevitt MR, Scheinberg DA. Ac-225 and her daughters: the many faces of Shiva. Cell Death Differ 2002; 9:593-594.
Sollini M, Marzo K, Chiti A, Kirienka M. The five “W”s and “How” of targeted alpha therapy: why? who? what? where? when? and how?. Rend Fis Acc Lincei 2020; 31:231–247.
Nilsson S, Larsen RH, Fosså SD, Balteskard L, Borch KW, Westlin JE, et al. First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res 2005; 11:4451–4459.
Kluetz PG, Pierce W, Maher VE, Zhang H, Tang S, Song P, et al. Radium Ra 223 dichloride injection: U.S. Food and Drug Administration drug approval summary. Clin Cancer Res 2014; 20:9–14.
Kirby HW. The discovery of Actinium. Isis 1971; 62:290-308.
National Center for Biotechnology Information (2022). PubChem element summary for atomicnumber 89, Actinium. Retrieved January 18, 2022. https://pubchem.ncbi.nlm.nih.gov/element/Actinium . Accessed 18 January 2022.
Fry C, Thoennessen M. Discovery of actinium, thorium, protactinium, and uranium isotopes. At Data Nucl Data Tables 2013; 99:345.
Kirby HW, Morss LR. Actinium. Morss LR, Edelstein NM, Fuger J, editors. In: The chemistry of the Actinide and transactinide elements. Springer; 2006. pp. 18-51.
Kim YS, Brechbiel MW. An overview of targeted alpha therapy. Tumour Biol 2012; 33:573–590.
Rasheed R, Usmani S, Naqvi SAR, Alkandari F, Marafi F. Alpha therapy with 225Actinium labeled prostate specific membrane antigen: reporting new photopeak of 78 Kilo-electron volts for better image statistics. Indian J Nucl Med 2019; 34:76–77.
Vatsa R, Sood A, Vadi SK, Das CK, Kaur K, Parmar M, Mittal BR. 225Ac-PSMA-617 radioligand posttherapy imaging in metastatic castrate-resistant prostate cancer patient using 3 photopeaks. Clin Nucl Med 2020; 45:437–438.
Alvarez R. Managing the Uranium-233 Stockpile of the United States. Sci Glob Secur 2013; 21:53-69.
Boll RA, Malkemus D, Mirzadeh S. Production of actinium-225 for alpha particle mediated radioimmunotherapy. Appl Radiat Isot 2005; 62:667–679.
Apostolidis C, Molinet R, Rasmussen G, Morgenstern A. Production of Ac-225 from Th-229 for targeted alpha therapy. Anal Chem 2005; 77:6288–6291.
Kotovskii AA, Nerozin NA, Prokof’ev IV, Shapovalov VV, Yakovshchits YA, Bolonkin AS, et al. Isolation of actinium-225 for medical purposes. Radiochem 2015; 57:285-291.
Morgenstern A, Apostolidis C, Bruchertseifer F. Supply and clinical application of actinium-225 and bismuth-213. Semin Nucl Med 2020; 50:119–123.
Perron R, Gendron D, Causey PW. Construction of a thorium/actinium generator at the Canadian Nuclear Laboratories. Appl Radiat Isot 2020; 164:109262.
IAEA. Report on joint IAEA-JRC workshop. Supply of actinium-225; 2018. IAEA website. http://www-naweb.iaea.org/napc/iachem/working_materials/Report_Workshop%20on%20Supply%20of%20Ac-225_IAEA_JRC_October2018.pdf . Accessed 18 January 2022.
Fitzsimmons J, Griswold J, Medvedev D, Cutler CS, Mausner L. Defining processing times for accelerator produced 225 Ac and other isotopes from proton irradiated thorium. Molecules 2019; 24:1095.
Melville G, Meriarty H, Metcalfe P, Knittel T, Allen BJ. Production of Ac-225 for cancer therapy by photon-induced transmutation of Ra-226. Appl Radiat Isot 2007; 65:1014–1022.
Melville G, Allen BJ. Cyclotron and linac production of Ac-225. Appl Radiat Isot 2009; 67:549–555.
Steyn GF, Motetshwane MA, Szelecsényi F, Brümmer JW. Pairing of thorium with selected primary target materials in tandem configurations: co-production of 225 Ac/ 213 Bi and 230 U/ 226 Th generators with a 70 MeV H- cyclotron. Appl Radiat Isot 2021; 168:109514.
Apostolidis C, Molinet R, McGinley J, Abbas K, Möllenbeck J, Morgenstern A. Cyclotron production of Ac-225 for targeted alpha therapy. Appl Radiat Isot 2005; 62:383–387.
Edelmann FT. Lanthanides and actinides: annual survey of their organometallic chemistry covering the year 2016. Coord Chem Rev 2017; 338:27-140.
Zielińska B, Bilewicz A. The hydrolysis of actinium. J Radioanal Nucl Chem 2004; 261:195-198.
Kulikov E, Novgorodov A, Schumann D. Hydrolysis of 225 Actinium trace quantities. J Radioanal Nucl Chem 1992; 164:103-108.
Thiele NA, Wilson JJ. Actinium-225 for targeted α therapy: coordination chemistry and current chelation approaches. Cancer Biother Radiopharm 2018; 33:336–348.
Pearson RG. Hard and soft acids and bases. J Am Chem Soc 1963; 85:3533-3539.
Cotton S. Introduction to the actinides. In: Cotton S, editor. Lanthanide and Actinide chemistry. John Wiley & Sons, Ltd; 2006. pp. 145-152.
Shahani CJ, Mathew KA, Rao CL, Ramaniah MV. Chemistry of Actinium. I. Stability constants of chloride, bromide, nitrate and sulphate complexes. Radiochim Acta 1968; 10:165-167.
Allen PG, Bucher JJ, Shuh DK, Edelstein NM, Craig I. Coordination chemistry of trivalent lanthanide and actinide ions in dilute and concentrated chloride solutions. Inorg Chem 2000; 39:595–601.
Brechbiel MW. Bifunctional chelates for metal nuclides. Q J Nucl Med Mol Imaging 2008; 52:166–173.
Robertson AKH, Ramogida CF, Schaffer P, Radchenko V. Development of 225 Ac radiopharmaceuticals: TRIUMF perspectives and experiences. Curr Radiopharm 2018; 11:156–172.
Nelson BJB, Andersson JD, Wuest F. Targeted alpha therapy: progress in radionuclide production, radiochemistry, and applications. Pharmaceutics 2020; 13:49.
Stein BW, Morgenstern A, Batista ER, Birnbaum ER, Bone SE, Cary SK, et al. Advancing chelation chemistry for Actinium and other +3 f-Elements, Am, Cm, and La. J Am Chem Soc 2019; 141:19404–19414.
Thiele NA, Brown V, Kelly JM, Amor-Coarasa A, Jermilova U, MacMillan SN, et al. An eighteen-membered macrocyclic ligand for Actinium-225 targeted alpha therapy. Angew Chem Int Ed Engl 2017; 56:14712–14717.
Ramogida CF, Robertson AKH, Jermilova U, Zhang C, Yang H, Kunz P, et al. Evaluation of polydentate picolinic acid chelating ligands and an α-melanocyte-stimulating hormone derivative for targeted alpha therapy using ISOL-produced 225 Ac. EJNMMI Radiopharm Chem 2019; 4:21.
Thijssen L, Schaart D, de Vries D, Morgenstern A, Bruchertseifer F, Denkova A. Polymersomes as nano-carriers to retain harmful recoil nuclides in alpha radionuclide therapy: a feasibility study. Radiochimica Acta 2012; 100:473-482.
De Kruijff RM, Wolterbeek HT, Denkova AG. A critical review of alpha radionuclide therapy—how to deal with recoiling daughters? Pharmaceuticals 2015; 8:321-336.
Jaggi JS, Kappel BJ, McDevitt MR, Sgouros G, Flombaum CD, Cabassa C, Scheinberg DA. Efforts to control the errant products of a targeted in vivo generator. Cancer Res 2005; 65:4888–4895.
Davis IA, Glowienka KA, Boll RA, Deal KA, Brechbiel MW, Stabin M, et al. Comparison of 225 actinium chelates: tissue distribution and radiotoxicity. Nucl Med Biol 1999; 26:581–589.
Sofou S, Thomas JL, Lin HY, McDevitt MR, Scheinberg DA, Sgouros G. Engineered liposomes for potential alpha-particle therapy of metastatic cancer. J Nucl Med 2004; 45:253–260.
McDevitt MR, Ma D, Lai LT, Simon J, Borchardt P, Frank RK, et al. Tumor therapy with targeted atomic nanogenerators. Science 2001; 294:1537–1540.
Cordier D, Forrer F, Bruchertseifer F, Morgenstern A, Apostolidis C, Good S, et al. Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213 Bi-DOTA-[Thi8,Met(O2)11]-substance P: a pilot trial. Eur J Nucl Med Mol Imaging 2010; 37:1335–1344.
Kelly JM, Amor-Coarasa A, Sweeney E, Wilson JJ, Causey PW, Babich JW. A suitable time point for quantifying the radiochemical purity of 225 Ac-labeled radiopharmaceuticals. EJNMMI Radiopharm Chem 2021; 6:38.
Kratochwil C, Bruchertseifer F, Rathke H, Bronzel M, Apostolidis C, Weichert W, et al. Targeted α-therapy of metastatic castration-resistant prostate cancer with 225 Ac-PSMA-617: dosimetry estimate and empiric dose finding. J Nucl Med 2017; 58:1624–1631.
Bolch WE, Eckerman KF, Sgouros G, Thomas SR. MIRD pamphlet No. 21: a generalized schema for radiopharmaceutical dosimetry–standardization of nomenclature. J Nucl Med 2009; 50:477–484.
Tafreshi NK, Tichacek CJ, Pandya DN, Doligalski ML, Budzevich MM, Kil H, et al. Melanocortin 1 receptor-targeted α-particle therapy for metastatic uveal melanoma. J Nucl Med 2019; 60:1124–1133.
Tafreshi NK, Pandya DN, Tichacek CJ, Budzevich MM, Wang Z, Reff JN, et al. Preclinical evaluation of [ 225 Ac]Ac-DOTA-TATE for treatment of lung neuroendocrine neoplasms. Eur J Nucl Med Mol Imaging 2021; 48:3408–3421.
Rossi HH, Zaider M. Applications of microdosimetry in biology. In: Microdosimetry and its applications. Springer; 1996.
Sgouros G, Roeske JC, McDevitt MR, Palm S, Allen BJ, Fisher DR, et al.; SNM MIRD Committee. MIRD Pamphlet No. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy. J Nucl Med 2010; 51:311–328.
Huang CY, Guatelli S, Oborn BM, Allen BJ. Microdosimetry for targeted alpha therapy of cancer. Comput Math Methods Med 2012; 2012:153212.
Hofmann W, Li WB, Friedland W, Miller BW, Madas B, Bardiès M, Balásházy I. Internal microdosimetry of alpha-emitting radionuclides. Radiat Environ Biophys 2020; 59:29–62.
Ludwig D, Bryan R, Dawicki W, Geoghegan EM, Liang Q, Seth S, et al. Preclinical development of an Actinium-225-labeled antibody radio-conjugate directed against CD45 for targeted conditioning and radioimmunotherapy. Blood 2019; 134:5601.
Pruszynski M, D’Huyvetter M, Bruchertseifer F, Morgenstern A, Lahoutte T. Evaluation of an Anti-HER2 nanobody labeled with 225 Ac for targeted α-particle therapy of cancer. Mol Pharm 2018; 15:1457–1466.
Solomon VR, Alizadeh E, Bernhard W, Hartimath SV, Hill W, Chekol R, et al. 111 In- and 225 Ac-labeled Cixutumumab for imaging and α-particle radiotherapy of IGF-1R positive triple-negative breast cancer. Mol Pharm 2019; 16:4807–4816.
Singh Jaggi J, Henke E, Seshan SV, Kappel BJ, Chattopadhyay D, May C, et al. Selective alpha-particle mediated depletion of tumor vasculature with vascular normalization. PLoS One 2007; 2:e267.
Cheal SM, McDevitt MR, Santich BH, Patel M, Yang G, Fung EK, et al. Alpha radioimmunotherapy using 225 Ac-proteus-DOTA for solid tumors - safety at curative doses. Theranostics 2020; 10:11359–11375.
Salvanou EA, Stellas D, Tsoukalas C, Mavroidi B, Paravatou-Petsotas M, Kalogeropoulos N, et al. A proof-of-concept study on the therapeutic potential of Au nanoparticles radiolabeled with the alpha-emitter Actinium-225. Pharmaceutics 2020; 12:E188.
Kelly JM, Amor-Coarasa A, Ponnala S, Nikolopoulou A, Williams C Jr, Thiele NA, et al. A single dose of 225 Ac-RPS-074 induces a complete tumor response in an LNCaP Xenograft model. J Nucl Med 2019; 60:649–655.
Kratochwil C, Bruchertseifer F, Giesel FL, Apostolidis C, Haberkorn U, Morgenstern A. Ac-225-DOTATOC-dose finding for alpha particle emitter based radionuclide therapy of neuroendocrine tumors. Eur J Nucl Med Mol Imaging 2015; 42:S36.
Juergens RA, Zukotynski KA, Juneau D, Krnezich L, Simms R, Forbes J, et al. A phase I study of [ 225 Ac]-FPI-1434 radioimmunotherapy in patients with IGF-1R expressing solid tumors. J Clin Onco 2019; 37:TPS3152-TPS3152.
Juneau D, Saad F, Berlin A, Metser U, Puzanov I, Lamonica D. Preliminary dosimetry results from a first-in-human Phase I study evaluating the efficacy and safety of [ 225 Ac]-FPI-1434 in patients with IGF-1R expressing solid tumors. J Nuc Med 2021; 62:S1-S74.
Królicki L, Bruchertseifer F, Kunikowska J, Koziara H, Pawlak D, Kuliński R, et al. Dose escalation study of targeted alpha therapy with [ 225 Ac]Ac-DOTA-substance P in recurrence glioblastoma - safety and efficacy. Eur J Nucl Med Mol Imaging 2021; 48:3595–3605.
Rosenblat TL, McDevitt MR, Pandit-Taskar N, Carrasquillo JA, Chanel S, Frattini MG, et al. Phase I trial of the targeted alpha-particle nano-generator Actinium-225 ( 225 Ac)-HuM195 (Anti-CD33) in Acute Myeloid Leukemia (AML). Blood 2007; 110: 910.
Jurcic JG. Clinical studies with bismuth-213 and actinium-225 for hematologic malignancies. Curr Radiopharm 2018; 11:192–199.
Tagawa ST, Vallabhajosula S, Jhanwar Y, Ballman KV, Hackett A, Emmerich L, et al. Phase I dose-escalation study of 225 Ac-J591 for progressive metastatic castration resistant prostate cancer (mCRPC). J Clin Oncol 2018; 36:TPS399-TPS399.
211 At-BC8-B10 Before donor stem cell transplant in treating patients with high-risk acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome, or mixed-phenotype acute leukemia. https://clinicaltrials.gov/ct2/show/NCT03128034
Zalutsky MR, Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, et al. Clinical experience with alpha-particle emitting 211 At: treatment of recurrent brain tumor patients with 211 At-labeled chimeric antitenascin monoclonal antibody 81C6. J Nucl Med 2008; 49:30–38.
Cederkrantz E, Andersson H, Bernhardt P, Bäck T, Hultborn R, Jacobsson L, et al. Absorbed doses and risk estimates of (211)At-MX35 F(ab’)2 in intraperitoneal therapy of ovarian cancer patients. Int J Radiat Oncol Biol Phys 2015; 93:569–576.
Müller C, Reber J, Haller S, Dorrer H, Köster U, Johnston K, et al. Folate receptor targeted alpha-therapy using terbium-149. Pharmaceuticals (Basel) 2014; 7:353–365.
Raja C, Graham P, Abbas Rizvi SM, Song E, Goldsmith H, Thompson J, et al. Interim analysis of toxicity and response in phase 1 trial of systemic targeted alpha therapy for metastatic melanoma. Cancer Biol Ther 2007; 6:846–852.
Królicki L, Bruchertseifer F, Kunikowska J, Koziara H, Królicki B, Jakuciński M, et al. Safety and efficacy of targeted alpha therapy with 213 Bi-DOTA-substance P in recurrent glioblastoma. Eur J Nucl Med Mol Imaging 2019; 46:614-622.
Kratochwil C, Giesel FL, Bruchertseifer F, Mier W, Apostolidis C, Boll R, et al. ²¹³Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience. Eur J Nucl Med Mol Imaging 2014; 41:2106–2119.
Borrebaek J, Grant D, Bjerke RM, Karlsson J, Cuthbertson AS. Targeted alpha therapy using a novel CD70 targeted thorium-227 conjugate in in vitro and in vivo models of renal cell carcinoma. Oncotarget 2017; 8:56311-56326.
Dobelbower MC, Lowy AM. Safety and outcome measures of first-in-human intraperitoneal α radioimmunotherapy with 212Pb-TCMC-Trastuzumab. Am J Clin Oncol 2018; 41:716-721.